Deals this week: Grifols, Cellesce, Arena Pharmaceuticals

Spanish pharmaceutical company Grifols has raised €1bn ($1.06bn) through a public offering of bonds.

Due 1 May 2025, the unsecured bonds carry a coupon rate of 3.2%.

The offering is intended to refinance the bonds issued by the company in March 2014.

UK-based biotechnology company Cellesce has completed a venture financing round led by Finance Wales in order to raise funds required to further develop its organoid expansion technology.

Part of the proceeds will also be used to establish the company’s growing team in the GE Innovation Village in Cardiff.

Arena Pharmaceuticals intends to raise $69m through an underwritten public offering of 60 million shares of its common stock.

"Arena Pharmaceuticals intends to raise $69m through an underwritten public offering of 60 million shares of its common stock."

The offering is priced at $1.15 a share and underwriters have a 30-day option to purchase up to nine million additional shares to cover any over-allotments.

The proceeds are intended to be used for general corporate purposes, as well as to acquire drugs, technologies, businesses or other assets.

Chinese company Tianjin CanSino Biotechnology has completed a venture financing round led by SDIC Future Industry Investment Fund in order to raise $65m.

The proceeds are intended to be used to develop vaccines.

Tetra Bio-Pharma has signed a co-distribution agreement with Aphria to distribute dried medical cannabis in the maritime provinces and Quebec, Canada.

Aphria will supply dried medical cannabis, while Tetra Bio-Pharma will complete the formulation and packaging.

Both companies involved in the transaction are based in Canada.